AAML1031: A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

ID Number 80-0066-01031

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)


In the United States, nearly 500 children, adolescents and young adults are diagnosed with AML every year and half are cured with standard therapy. In other words, half of the children, adolescents and young adults diagnosed with AML remain with no signs of cancer (remission) for 5 years. The overall goal of this study is to see if we can increase this cure rate without causing more serious side effects of therapy. Side effects are unintended and unwanted results of treatment.

Contact Information
Katrina Watson
(212) 241-6906

Recruiting Patients: Yes